½ÃÀ庸°í¼­
»óǰÄÚµå
1598758

Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå : Á¦Ç°º°, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Umbilical Cord Blood Processing Products Market by Product (CD Markers, Cell Culture Devices, Cell Culture Reagents), End-Users (Private Banks, Public Banks) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 183 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀåÀº 2023³â 15¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í 2024³â¿¡´Â 16¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGR 10.93%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 31¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¦´ëÇ÷ ó¸® Á¦Ç°¿¡´Â Á¦´ëÇ÷ À¯·¡ Á¶Ç÷¸ð¼¼Æ÷(Á¶Ç÷¸ð¼¼Æ÷)ÀÇ Ã¤Ãë, ó¸®, º¸Á¸, ³Ãµ¿º¸Á¸¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ ±â¼ú°ú Àåºñ°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ ½ÃÀåÀº ¹éÇ÷º´, ¸²ÇÁÁ¾, ¸é¿ªÁúȯ µî »ý¸íÀ» À§ÇùÇÏ´Â ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ Áٱ⼼Æ÷ÀÇ Àû¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, °ñ¼ö À̽Ŀ¡ ´ëÇÑ ´ë¾ÈÀ» Á¦°øÇϱ⠶§¹®¿¡ ¸Å¿ì Áß¿äÇÑ ½ÃÀåÀÔ´Ï´Ù. Áٱ⼼Æ÷ÀÇ ¿ëµµ¿Í ÃÖÁ¾ ¿ëµµ´Â Àç»ýÀÇ·á¿Í ¸ÂÃãÄ¡·á¿¡ ÁßÁ¡À» µÐ º´¿ø, ¿¬±¸±â°ü, Ä¡·á¼¾ÅÍ·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â Áٱ⼼Æ÷ Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, »ý¸í°øÇÐ ±â¼úÀÇ ¹ßÀü, Á¦´ëÇ÷ ÀºÇà¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. °ø°ø ¹× ¹Î°£ Á¦´ëÇ÷ ÀºÇàÀÌ Àü ¼¼°èÀûÀ¸·Î ¼­ºñ½º¸¦ È®´ëÇÔ¿¡ µû¶ó À̵é Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áٱ⼼Æ÷ÀÇ »ýÁ¸À²°ú ¼öÀ²À» Çâ»ó½Ã۱â À§ÇÑ ÀÚµ¿È­µÇ°í È¿À²ÀûÀΠó¸® ±â¼ú °³¹ß°ú ±âÁõÀÚÀÇ ´Ù¾ç¼ºÀ» ³ôÀ̱â À§ÇÑ Ã¤Ãë ³×Æ®¿öÅ©ÀÇ È®´ë°¡ ±âȸ·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ¿î¿µ ºñ¿ë, ¾ö°ÝÇÑ ¿¬±¸ ±ÔÁ¦, Áٱ⼼Æ÷ ¿¬±¸ ¹× Ä¡·á¸¦ µÑ·¯½Ñ À±¸®Àû ¿ì·Á´Â ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³¹ßµµ»ó±¹¿¡¼­ÀÇ ÀÎ½Ä ºÎÁ·°ú ÀûÀýÇÑ Á¦´ëÇ÷ äÃë ¹× º¸Á¸À» À§ÇÑ ÀÎÇÁ¶ó ±¸ÃàÀÌ ¹ÌÈíÇÑ °Íµµ ÇѰè·Î ²ÅÈü´Ï´Ù. ³Ãµ¿ º¸Á¸ ±â¼ú ¹× »õ·Î¿î ¼¼Æ÷ ºÐ¸® ¹æ¹ýÀÇ °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃá ±â¼ú Çõ½ÅÀº ½ÃÀå È®´ëÀÇ À¯¸ÁÇÑ °æ·Î¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, °øµ¿¿¬±¸¸¦ ÅëÇØ Á¦´ëÇ÷ À¯·¡ Áٱ⼼Æ÷ÀÇ Ä¡·á °¡´É¼ºÀ» ¹àÇô³»´Â µ¥ Å« ÁøÀüÀ» ÀÌ·ê ¼ö ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ Æ¯¼ºÀº ±â¼ú ¹ßÀü°ú ÀÇ·á ÆÐ·¯´ÙÀÓÀÇ º¯È­·Î ÀÎÇØ ºü¸£°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϰí ÀÇ·á ¼­ºñ½º Á¦°øÀÚ ¹× ¿¬±¸ ±â°ü°ú Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ¸ÎÀ½À¸·Î½á ÀÌ·¯ÇÑ ¿ªµ¿¼ºÀ» Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î, Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀåÀÇ ¼ºÀåÀ» À¯ÁöÇϱâ À§Çؼ­´Â ±ÔÁ¦ À̽´¿¡ ´ëÀÀÇÏ°í »çȸÀû ÀÎÁöµµ¸¦ ³ôÀÌ´Â µ¥ ÁßÁ¡À» µÎ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ[2023] 15¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2024] 16¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2030] 31¾ï 6,000¸¸ ´Þ·¯
CAGR(%) 10.93%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù

Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀåÀº ¼ö¿ä¿Í °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î ÀÎÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ÃËÁø¿äÀÎ
    • ¸¸¼ºÁúȯÀÇ Áõ°¡·Î ÀÎÇÑ ¼ºÀå
    • Á¦´ëÇ÷ ÀºÇàÀÇ Àû¿ë¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ °ø°ø ¹× ¹Î°£ Ä·ÆäÀÎÀÌ È°¹ßÈ÷ ÁøÇà ÁßÀÓ.
    • Ç÷¾× Áúȯ ¹× Ç÷¾×¾ÏÀÇ À¯º´·ü Áõ°¡
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • Á¦´ëÇ÷ÀºÇ༾ÅÍ ¼³¸³À» À§ÇÑ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÅÁ¦Ç° µîÀå
    • Á¦´ëÇ÷ Áٱ⼼Æ÷ ¿¬±¸ ¹× ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ÅõÀÚ
  • ½ÃÀå °úÁ¦
    • ¿ø·á ¹× ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·

Porter's Five Forces : Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï »óȲÀ» ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå¿¡¼­ÀÇ °æÀï »óȲ ÆÄ¾Ç

Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå¿¡¼­ÀÇ °ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ±â¾÷Àº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» ´Þ¼ºÇÒ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï »óȲÀ» öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õÀÇ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå : Á¦Ç°º°

  • CD ¸¶Ä¿
  • ¼¼Æ÷¹è¾ç Àåºñ
  • ¼¼Æ÷¹è¾ç ½Ã¾à
  • ȣȯ¼º ÀÖ´Â ¹é°ú ¿À¹ö·¦
  • Á¦´ëÇ÷ äÃë ½Ã½ºÅÛ
  • Àü¼Û, ó¸®, µ¿°á ¼¼Æ®
  • ¼öÇ÷ ¼¼Æ®
  • ÃÊÀú¿Â ¾×ü Áú¼Ò ³Ãµ¿°í
  • ¼¼Å¹ ¼¼Æ®

Á¦7Àå Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¹Î°£ÀºÇà
  • °øÀû ÀºÇà

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á¦´ëÇ÷ ó¸® Á¦Ç° ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦11Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abcam PLC
  • BioLegend, Inc.
  • Biologics International Corp.
  • Cryo-Cell International, Inc.
  • Immucor, Inc.
  • Nikkiso Co., Ltd.
  • Novus Biologicals
  • Pall Corporation
  • Prospec-Tany Technogene Ltd.
  • Proteintech Group, Inc.
  • Sartorius AG
  • Sino Biological Inc.
  • ViroGen
ksm 24.11.29

The Umbilical Cord Blood Processing Products Market was valued at USD 1.53 billion in 2023, expected to reach USD 1.69 billion in 2024, and is projected to grow at a CAGR of 10.93%, to USD 3.16 billion by 2030.

Umbilical cord blood processing products encompass a range of technologies and equipment used for the collection, processing, storage, and cryopreservation of hematopoietic stem cells (HSCs) derived from umbilical cord blood. This market is crucial due to the increasing application of stem cells in treating various life-threatening diseases like leukemia, lymphoma, and immune disorders, providing an alternative to bone marrow transplants. The application and end-use scope extend to hospitals, research institutes, and therapeutic centers focusing on regenerative medicine and personalized treatments. Key growth factors influencing the market include the rising awareness of stem cell therapies, advancements in biotechnology, and regulatory support for cord blood banking. The demand for these products is expected to surge as public and private cord blood banks expand their services globally. Opportunities lie in developing automated and efficient processing technologies to enhance the viability and yield of stem cells, along with expanding collection networks to increase donor diversity. However, market growth is challenged by high operational costs, stringent regulatory requirements, and ethical concerns surrounding stem cell research and therapy. Limitations also include the lack of awareness in developing regions and inadequate infrastructure for proper cord blood collection and storage. Innovations focusing on improving cryopreservation techniques and novel cell separation methods offer promising avenues for market expansion. Furthermore, collaborative research initiatives could unlock substantial advancements in understanding the therapeutic potential of umbilical cord blood-derived stem cells. The nature of this market is rapidly evolving, driven by technological advances and changing healthcare paradigms. Businesses can leverage these dynamics by investing in R&D and forming strategic partnerships with healthcare providers and research institutions. Overall, maintaining strong focus on addressing regulatory challenges and increasing public awareness is essential for sustaining growth in the umbilical cord blood processing products market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.53 billion
Estimated Year [2024] USD 1.69 billion
Forecast Year [2030] USD 3.16 billion
CAGR (%) 10.93%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Umbilical Cord Blood Processing Products Market

The Umbilical Cord Blood Processing Products Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing due to the increasing prevalence of chronic diseases
    • Favorable public and private campaigns generating awareness regarding applications of cord banking
    • Increasing prevalence of hematological disorders and blood cancer
  • Market Restraints
    • High cost for setting up cord blood banking centers
  • Market Opportunities
    • Emergence of new product launches of UC blood processing products
    • Favorable government investments in research and clinical trials of cord blood stem cells
  • Market Challenges
    • Lack of raw materials and skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Umbilical Cord Blood Processing Products Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Umbilical Cord Blood Processing Products Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Umbilical Cord Blood Processing Products Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Umbilical Cord Blood Processing Products Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Umbilical Cord Blood Processing Products Market

A detailed market share analysis in the Umbilical Cord Blood Processing Products Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Umbilical Cord Blood Processing Products Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Umbilical Cord Blood Processing Products Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Umbilical Cord Blood Processing Products Market

A strategic analysis of the Umbilical Cord Blood Processing Products Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Umbilical Cord Blood Processing Products Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, BioLegend, Inc., Biologics International Corp., Cryo-Cell International, Inc., Immucor, Inc., Nikkiso Co., Ltd., Novus Biologicals, Pall Corporation, Prospec-Tany Technogene Ltd., Proteintech Group, Inc., Sartorius AG, Sino Biological Inc., and ViroGen.

Market Segmentation & Coverage

This research report categorizes the Umbilical Cord Blood Processing Products Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across CD Markers, Cell Culture Devices, Cell Culture Reagents, Compatible Bags & Over Wraps, Cord Blood Collection Systems, Transfer, Processing & Freezing Sets, Transfusion Sets, Ultra-Cold Liquid Nitrogen Freezers, and Washing Sets.
  • Based on End-Users, market is studied across Private Banks and Public Banks.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing due to the increasing prevalence of chronic diseases
      • 5.1.1.2. Favorable public and private campaigns generating awareness regarding applications of cord banking
      • 5.1.1.3. Increasing prevalence of hematological disorders and blood cancer
    • 5.1.2. Restraints
      • 5.1.2.1. High cost for setting up cord blood banking centers
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of new product launches of UC blood processing products
      • 5.1.3.2. Favorable government investments in research and clinical trials of cord blood stem cells
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of raw materials and skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Umbilical Cord Blood Processing Products Market, by Product

  • 6.1. Introduction
  • 6.2. CD Markers
  • 6.3. Cell Culture Devices
  • 6.4. Cell Culture Reagents
  • 6.5. Compatible Bags & Over Wraps
  • 6.6. Cord Blood Collection Systems
  • 6.7. Transfer, Processing & Freezing Sets
  • 6.8. Transfusion Sets
  • 6.9. Ultra-Cold Liquid Nitrogen Freezers
  • 6.10. Washing Sets

7. Umbilical Cord Blood Processing Products Market, by End-Users

  • 7.1. Introduction
  • 7.2. Private Banks
  • 7.3. Public Banks

8. Americas Umbilical Cord Blood Processing Products Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Umbilical Cord Blood Processing Products Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Umbilical Cord Blood Processing Products Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abcam PLC
  • 2. BioLegend, Inc.
  • 3. Biologics International Corp.
  • 4. Cryo-Cell International, Inc.
  • 5. Immucor, Inc.
  • 6. Nikkiso Co., Ltd.
  • 7. Novus Biologicals
  • 8. Pall Corporation
  • 9. Prospec-Tany Technogene Ltd.
  • 10. Proteintech Group, Inc.
  • 11. Sartorius AG
  • 12. Sino Biological Inc.
  • 13. ViroGen
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦